The comorbidity of bipolar disorder and migraine: The role of inflammation and oxidative and nitrosative stress

Current Molecular Medicine

Volumn 16, Issue 2, 2016, Pages 179-186

  da Costa, S C ^a   Passos, I C ^a   Reus G Z ^a,c   Carvalho, A F ^d   Soares, J C ^a   Quevedo, J ^a,b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Bipolar disorder; Inflammation; Migraine; Nitrosative stress; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; 8 ISOPROSTANE; ARACHIDONIC ACID DERIVATIVE; CD11B ANTIGEN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MOOD STABILIZER; MYELOID DIFFERENTIATION FACTOR 88; NITRIC OXIDE; PEROXYNITRITE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROSTAGLANDIN E; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; VALPROIC ACID; VON WILLEBRAND FACTOR;

ARTICLE; BIPOLAR DISORDER; CELL ACTIVATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CROSS ALLERGY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; HOMEOSTASIS; HUMAN; IMMUNE DYSREGULATION; INFLAMMATION; MACROPHAGE; MENTAL STRESS; META ANALYSIS (TOPIC); MIGRAINE; NERVOUS SYSTEM INFLAMMATION; NITROSATIVE STRESS; ONCOGENE C FOS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL STRESS; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR; T LYMPHOCYTE; COMPLICATION; NITROSATION; PATHOLOGY;

BIPOLAR DISORDER; COMORBIDITY; HUMANS; INFLAMMATION; MIGRAINE DISORDERS; NITROSATION; OXIDATIVE STRESS;

EID: 84958966879     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524016666160126144440     Document Type: Article

References (92)

1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64(5): 543-52.
2. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152(11): 1635-40.
3. Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 2011; 68(10): 1058-64.
4. Crump C, Sundquist K, Winkleby MA, Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013; 70(9): 931-9.
5. Gardner HH, Kleinman NL, Brook RA, Rajagopalan K, Brizee TJ, Smeeding JE. The economic impact of bipolar disorder in an employed population from an employer perspective. J Clin Psychiatry 2006; 67(8): 1209-18.
6. Lofland JH, Frick KD. Workplace absenteeism and aspects of access to health care for individuals with migraine headache. Headache 2006; 46(4): 563-76.
7. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998; 38(2): 87-96.
8. McIntyre RS, Konarski JZ, Wilkins K, Bouffard B, Soczynska JK, Kennedy SH. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache 2006; 46(6): 973-82.
9. Forty L, Ulanova A, Jones L, et al. Comorbid medical illness in bipolar disorder. Br J Psychiatry 2014; 205(6): 465-72.
10. Brietzke E, Moreira CLRL, Duarte SVB, et al. Impact of comorbid migraine on the clinical course of bipolar disorder. Compr Psychiatry 2012; 53(6): 809-12.
11. Saunders EFH, Nazir R, Kamali M, et al. Gender differences, clinical correlates, and longitudinal outcome of bipolar disorder with comorbid migraine. J Clin Psychiatry 2014; 75(5): 512-9.
12. Nguyen T-V, Low NC. Comorbidity of migraine and mood episodes in a nationally representative population-based sample. Headache 2013; 53(3): 498-506.
13. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders--a national population-based study. Headache 2008; 48(4): 501-16.
14. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45 Suppl 1: S3-13.
15. Marino E, Fanny B, Lorenzi C, et al. Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. Neurol Sci 2010; 31(3): 387-91.
16. Oedegaard KJ, Greenwood TA, Johansson S, et al. A genome-wide association study of bipolar disorder and comorbid migraine. Genes Brain Behav 2010; 9(7): 673-80.
17. Brown NC, Andreazza AC, Young LT. An updated metaanalysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014; 218(1-2): 61-8.
18. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35(3): 804-17.
19. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 2013; 74(1): 15-25.
20. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009; 70(8): 1078-90.
21. Schroeter ML, Steiner J, Mueller K. Glial pathology is modified by age in mood disorders-A systematic metaanalysis of serum S100B in vivo studies. J Affect Disord 2011; 134(1-3): 32-8.
22. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35(4): 298-306.
23. Smith RS, Maes M. The Macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med Hypotheses 1995; 45(2): 135-41.
24. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior. Neuropsychopharmacology 2012; 37(1): 137-62.
25. Gallo V, Deneen B. Glial Development: The Crossroads of Regeneration and Repair in the CNS. Neuron 2014; 83(2): 283-308.
26. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010; 15(4): 384-92.
27. Kim H-W, Rapoport SI, Rao JS. Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry 2011; 16(4): 419-28.
28. Haarman BC, Riemersma-Van der Lek RF, de Groot JC, et al. Neuroinflammation in bipolar disorder-A [(11)C]-(R)-PK11195 positron emission tomography study. Brain Behav Immun 2014; 40: 219-25.
29. Chen PS, Wang C-C, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149(1): 203-12.
30. Dong H, Zhang X, Dai X, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J Neuroinflammation 2014; 11(1): 140.
31. Munkholm K, Brauner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47(9): 1119-33.
32. Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144(1-2): 16-27.
33. Bai Y-M, Su T-P, Tsai S-J, et al. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord 2014; 166: 187-92.
34. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002; 59(7): 592-6.
35. Rao JS, Lee H-J, Rapoport SI, Bazinet RP. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry 2008; 13(6): 585-96.
36. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2009; 2(2): 207-14.
37. Stolk P, Souverein PC, Wilting I, et al. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fatty Acids 2010; 82(1): 9-14.
38. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: A double-blind, randomized, placebocontrolled study. Hum Psychopharmacol 2008; 23(2): 87-94.
39. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70(1): 31-41.
40. Sies H. Oxidative stress: from basic research to clinical application. Am J Med 1991; 91(3C): 31S-38S.
41. Lowenstein CJ, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994; 120(3): 227-37.
42. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271(5 Pt 1): C1424-37.
43. Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry 2013; 47(4): 321-32.
44. Andreazza AC, Kauer-Sant'anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 2008; 111(2-3): 135-44.
45. Pandya CD, Howell KR, Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 214-23.
46. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res 2014; 56: 18-27.
47. Gigante AD, Young LT, Yatham LN, et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. Int J Neuropsychopharmacol 2011; 14(8): 1075-89.
48. Fries GR, Vasconcelos-Moreno MP, Gubert C, et al. Early apoptosis in peripheral blood mononuclear cells from patients with bipolar disorder. J Affect Disord 2014; 152-154: 474-7.
49. Yumru M, Savas HA, Kalenderoglu A, Bulut M, Celik H, Erel O. Oxidative imbalance in bipolar disorder subtypes: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(6): 1070-4.
50. Wang J-F, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11(5): 523-9.
51. Versace A, Andreazza AC, Young LT, et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014; 19(2): 200-8.
52. Andreazza AC, Wang J-F, Salmasi F, Shao L, Young LT. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem 2013; 127(4): 552-61.
53. Soeiro-De-Souza MG, Stanford MS, Bio DS, Machado-Vieira R, Moreno RA. Association of the COMT Met158 allele with trait impulsivity in healthy young adults. Mol Med Rep 2013; 7(4): 1067-72.
54. Abe N, Uchida S, Otsuki K, et al. Altered sirtuin deacetylase gene expression in patients with a mood disorder. J Psychiatr Res 2011; 45(8): 1106-12.
55. Moylan S, Berk M, Dean OM, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46-62.
56. Gubert C, Stertz L, Pfaffenseller B, et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J Psychiatr Res 2013; 47(10): 1396-402.
57. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61(3): 300-8.
58. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by largescale DNA microarray analysis. Hum Mol Genet 2005; 14(2): 241-53.
59. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 2006; 11(3): 241-51.
60. Passos JF, Saretzki G, Ahmed S, et al. Mitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence. PLoS Biol 2007; 5(5): e110.
61. Simon NM, Smoller JW, McNamara KL, et al. Telomere Shortening and Mood Disorders: Preliminary Support for a Chronic Stress Model of Accelerated Aging. Biol Psychiatry 2006; 60(5): 432-5.
62. de Sousa RT, Zarate CA, Zanetti MV, et al. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. J Psychiatr Res 2014; 50: 36-41.
63. Albayrak A, Halici Z, Polat B, et al. Protective effects of lithium: a new look at an old drug with potential antioxidative and anti-inflammatory effects in an animal model of sepsis. Int Immunopharmacol 2013; 16(1): 35-40.
64. Perini F, D'Andrea G, Galloni E, et al. Plasma cytokine levels in migraineurs and controls. Headache 2005; 45(7): 926-31.
65. Sarchielli P. Trigger factors of migraine and tension-type headache. J Headache Pain 2006; 7(4): 172-3.
66. Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache 2013; 53: 1262-77.
67. Tietjen GE, Herial NA, White L, Utley C, Kosmyna JM, Khuder SA. Migraine and biomarkers of endothelial activation in young women. Stroke 2009; 40(9): 2977-82.
68. Bruno PP, Carpino F, Carpino G, Zicari A. An overview on immune system and migraine. Eur Rev Med Pharmacol Sci 11(4): 245-8.
69. Gervil M, Ulrich V, Kyvik KO, Olesen J, Russell MB. Migraine without aura: a population-based twin study. Ann Neurol 1999; 46(4): 606-11.
70. de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. Molecular genetics of migraine. Hum Genet 2009; 126(1): 115-32.
71. Bigal ME, Lipton RB, Winner P, Reed ML, Diamond S, Stewart WF. Migraine in adolescents: association with socioeconomic status and family history. Neurology 2007; 69(1): 16-25.
72. Kemper RH, Meijler WJ, Korf J, Ter Horst GJ. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 2001; 21(5): 549-57.
73. Boettger MK, Weber K, Grossmann D, et al. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral i. Arthritis Rheum 2010; 62(5): 1308-18.
74. Schafers M, Sommer C, Geis C, Hagenacker T, Vandenabeele P, Sorkin LS. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience 2008; 157(2): 414-23.
75. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010; 7(2): 183-90.
76. Furchgott RF, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288(5789): 373-6.
77. Tuncel D, Tolun FI, Gokce M, Imrek S, Ekerbicer H. Oxidative stress in migraine with and without aura. Biol Trace Elem Res 2008; 126(1-3): 92-7.
78. Ciancarelli I, Tozzi-Ciancarelli MG, Spacca G, Di Massimo C, Carolei A. Relationship between biofeedback and oxidative stress in patients with chronic migraine. Cephalalgia 2007; 27(10): 1136-41.
79. Bernecker C, Ragginer C, Fauler G, et al. Oxidative stress is associated with migraine and migraine-related metabolic risk in females. Eur J Neurol 2011; 18(10): 1233-9.
80. Neri M, Frustaci A, Milic M, et al. A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. Cephalalgia 2015; 35(10): 931-7.
81. Tozzi-Ciancarelli MG, De Matteis G, Di Massimo C, Marini C, Ciancarelli I, Carolei A. Oxidative stress and platelet responsiveness in migraine. Cephalalgia 1997; 17(5): 580-4.
82. Gupta R, Kumar V, Luthra K, Banerjee B, Bhatia MS. Polymorphism in apolipoprotein E among migraineurs and tension-type headache subjects. J Headache Pain 2009; 10(2): 115-20.
83. De Matteis G, Tozzi-Ciancarelli MG, Calisse P, et al. Platelet changes in classic migraine. Ital J Neurol Sci 1993; 14(3): 207-10.
84. Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Marini C, Carolei A. Urinary nitric oxide metabolites and lipid peroxidation by-products in migraine. Cephalalgia 2003; 23(1): 39-42.
85. Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Marini C, Carolei A. Flunarizine effects on oxidative stress in migraine patients. Cephalalgia 2004; 24(7): 528-32.
86. Low NCP, Du Fort GG, Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003; 43(9): 940-9.
87. Oedegaard KJ, Fasmer OB. Is migraine in unipolar depressed patients a bipolar spectrum trait? J Affect Disord 2005; 84(2-3): 233-42.
88. Ortiz A, Cervantes P, Zlotnik G, et al. Cross-prevalence of migraine and bipolar disorder. Bipolar Disord 2010; 12(4): 397-403.
89. Vargas HO, Nunes SOV, Pizzo de Castro M, et al. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J Affect Disord 2013; 150(3): 923-30.
90. Gordon-Smith K, Forty L, Chan C, et al. Rapid cycling as a feature of bipolar disorder and comorbid migraine. J Affect Disord 2015; 175: 320-4.
91. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun 2015; 43: 205-13.
92. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol 2013; 16(7): 1505-12.